Donald Trump wearing a ‘hidden leg brace' to treat nerve damage? Speculation grows after US President's Air Force One stumble
These rumors come just weeks after Trump's physician, Captain Sean Barbabella, declared him to be in 'excellent cognitive and physical health.'
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Speculation over U.S. President Donald Trump 's health has intensified after he was seen stumbling while boarding Air Force One—and an unusual bulge under his pant leg has now sparked theories that he may be wearing a concealed leg brace.A photo shared by a Twitter user shows what appears to be a strange outline beneath Trump's trousers, prompting online chatter that he could be wearing Ankle Foot Orthotics (AFOs)—devices often prescribed for individuals with foot drop, a condition caused by nerve damage, according to a report by The Daily Boulder.These rumors come just weeks after Trump's physician, Captain Sean Barbabella, declared him to be in 'excellent cognitive and physical health.' In April, Trump underwent nearly five hours of medical evaluation at Walter Reed National Military Medical Center, including blood tests, cardiac screenings, ultrasounds, and a full neurological assessment.He also reportedly scored a perfect 30/30 on the Montreal Cognitive Assessment. 'I got the highest mark,' Trump said at the time. 'Good heart, a good soul—very good soul.'The most recent incident occurred Sunday in Morristown, New Jersey, as Trump boarded Air Force One en route to Washington, D.C. Video footage shows him stumbling while gripping the handrail, catching his left foot on a step before quickly regaining his balance and continuing up the stairs.Interestingly, Secretary of State Marco Rubio also stumbled while boarding the aircraft that day. Though both recovered swiftly, Trump's misstep went viral on social media, with many users drawing comparisons to past incidents involving President Joe Biden In 2023, Trump mocked Biden for falling to his knees at the Air Force graduation ceremony in Colorado. 'I hope he wasn't hurt… you don't want that,' Trump said, while also referencing his own careful descent down a slippery ramp at West Point in 2020. 'You've got to be careful about that—even if you have to tiptoe down a ramp.'At the time, Trump had criticized Biden for what he called an inability to "walk up a flight of stairs on Air Force One" or "put two sentences together," describing the Biden administration as incompetent.Now, with Trump himself under scrutiny over a potential leg brace, the political narrative around age, health, and fitness is again under the spotlight.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
5 hours ago
- Mint
NIH Grant Cuts Arent Saving Money. Theyre Wasting It.
(Bloomberg Opinion) -- The Trump administration's waves of massive cuts to funding at the National Institutes of Health are framed as a recasting of research priorities and a way to save taxpayer money. Another way to frame it is an exercise in massive waste. In terminating nearly 750 NIH grants over the past two months, the government dumped years of investment down the drain. The unceremonious end to those projects means we won't know the answers to studies that intended to improve the health of Americans. According to a Bloomberg Opinion analysis(1), Health and Human Services data show that some $373 million had already been spent on the 242 discontinued R01 grants, an NIH award that is considered critical to launching a successful career. Researchers tend to get that chunk of funding — typically a sizable amount that supports their work for 3 to 5 years — after they've done a few years of preliminary work. It's all geared toward asking a big scientific question. Our analysis doesn't include the untold number of NIH grants at Harvard University affected by the administration's $2.2 billion federal funding freeze this week — a punishment for refusing to comply with the government's long list of demands. But even if those funds are eventually restored, the disruption risks derailing studies related to ALS, tuberculosis and many other health conditions. Funding was pulled just as some of these projects were getting off the ground, while others were rounding into their last year of funding — a point where enough data would finally be collected to offer concrete results. Our analysis found that nearly 40% of the canceled R01 grants supported research that had yet to produce findings, meaning all of the agency's prior investments won't benefit the public. Take, for example, the abrupt end to Washington University of St. Louis professor Jeremy Goldbach's five-year grant to test the first evidence-backed intervention intended to help teachers, administrators and social workers support LGBTQ youth. A little over three years in, Goldbach had collected a massive amount of data from 20 schools — thousands of students had participated. But without his last rounds of funding, he won't be able to track the program's efficacy at the last four schools needed for the results to be statistically meaningful. That's more than $2.1 million that NIH already spent on the project down the drain, all because the government pulled the last few hundred thousand. (Goldbach's grant was one of many caught up in a sweep of cuts related to President Trump's gender ideology executive order.) But the loss goes beyond that. Goldbach's project built off years of earlier work. Before getting to the point where a review panel of more than two dozen experts felt the concept was promising enough to merit a large-scale study, the researcher had to design and test it. That work was supported by two earlier awards from NIH and financial help from foundations, which together amounted to nearly $900,000 in investment in the project. Moreover, about 15 people's jobs are on the line between the loss of this funding and around seven other terminated grants for studies that Goldbach is a collaborator on. At the other end of the spectrum, Northwestern University professor Michelle Birkett's $3.8 million grant was ended in the first of its five years. The funding was awarded to understand —and ultimately address — disparities in HIV transmission and substance use among gay men and transgender women. Although only a fraction of that promised money had been spent, Birkett had invested years of work into designing and securing funding for the study and had already recruited a community board across each of the five cities where it was poised to launch. Countless stories of similarly needless waste — research interrupted midstream and sidelined careers— live behind the HHS's long list of canceled funding. That translates into a massive number of health insights the public simply won't know about — yet had already paid to support. So many of those unanswered questions centered on prevention: How can we encourage simple changes that could have a big impact on the physical and mental health of Americans — and ultimately save the health care system money? For example, a cluster of projects devoted to improving uptake of the HPV vaccine, which has stalled in recent years, was among the research that recently lost funding. Not enough adolescents are getting the shots despite a growing body of data showing its ability to prevent deaths from cervical cancer in women and potentially lower the rates of head and neck, anal, penile, vaginal and vulvar cancers. Some of those HPV vaccine studies were well underway but, as with Goldbach's project, had yet to enroll enough volunteers to yield meaningful data on how to convince people to get the shot. Ultimately, that doesn't just waste the taxpayer money already spent on those grants; it could also cost the health care system later, in the form of otherwise preventable cancer cases. Abandoning these projects is far from an exercise in efficiency, as the Trump administration likes to tout. A more accurate word to sum up what's happening with these cuts would be: nonsensical. More From Bloomberg Opinion: Want more Bloomberg Opinion? OPIN GO. Or subscribe to our daily newsletter. (1) Bloomberg Opinion analyzed 748 terminated NIH grants from the HHS TAGGS data as of April 16. We merged in additional information about each grant, including the project start date and the number of associated publications, from the NIH RePORTER database. The length of each study is the time between the project's beginning and the grant termination date, which we visualize for three of the most common award types: R01, U01 and U54 grants. The funding already spent on R01s is calculated from the 'total amount expended' field in the HHS data. This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. Carolyn Silverman is a data journalist for Bloomberg Opinion. She previously served as a data scientist for the University of Chicago Crime Lab and Education Lab. More stories like this are available on
Economic Times
7 hours ago
- Economic Times
Bryan Johnson's new biohacking experiment is turning his bathroom breaks ‘blue'. Could it be the key to 'live forever'?
Bryan Johnson, the multi-millionaire entrepreneur who has turned anti-ageing into a full-time science experiment, has done it again—this time by revealing that his latest attempt at biological immortality has turned his urine a bright shade of blue. ADVERTISEMENT The 47-year-old, best known for spending over $2 million annually in a bid to reverse aging through his project Blueprint, recently posted on X (formerly Twitter), 'My urine is now blue,' adding that he had just begun a new treatment: methylene blue. It might sound like a joke, but it's anything but. Methylene blue is a real, FDA-approved chemical compound that's been used in medicine for more than a century. And for Johnson, it's just the latest in a long line of biohacking tools he believes will help him defy death. Methylene blue, also known as methylthioninium chloride, is a cobalt-blue dye initially developed in the 19th century to stain textiles. Later, it found a second life in medicine, treating a rare condition called methemoglobinemia—a disorder where the blood can't carry oxygen efficiently, resulting in symptoms like blue-tinged skin, shortness of breath, and even seizures. According to the FDA, methylene blue is useful for treating specific types of blood disorders, cyanide poisoning, and certain neurological conditions. But in the wellness and biohacking world, it has recently been hyped for its mitochondrial-boosting properties. Biohackers claim it can supercharge the tiny engines inside your cells, potentially leading to more energy, better memory, and even anti-aging effects. Johnson isn't alone; a growing number of health influencers have touted its benefits—though scientific consensus is still pending. ADVERTISEMENT When asked by a user why he'd take a synthetic, petroleum-based dye, Johnson joked: 'Was really moved by the Smurfs movie.' If drinking methylene blue seems extreme, it's only a sliver of Johnson's full lifestyle. The founder of Kernel, who once made headlines for injecting himself with his 17-year-old son's plasma, is infamous for his ultra-strict diet, exercise regimen, and reliance on experimental therapies. ADVERTISEMENT His biological metrics, he claims, prove it's working: a heart comparable to a 37-year-old's, lung capacity like an 18-year-old's, and in one test, the skin elasticity of a 10-year-old. Now, with this latest methylene blue experiment, Johnson says he feels 'like I'm in Avatar.' Despite the hype, methylene blue is not risk-free. The FDA warns of dangerous reactions when combined with psychiatric medications, particularly due to a potentially life-threatening condition called Serotonin Syndrome. ADVERTISEMENT According to a report by StatPearls Publishing, people with G6PD deficiency—an enzyme disorder—should never take it, as it can cause severe blood issues. It's also not safe for pregnant women, people with kidney problems, or anyone who's had an allergic reaction to it in the past. As such, experts urge caution. While some studies suggest potential benefits, Harvard Health Publishing notes that more research is needed before methylene blue becomes a mainstream wellness treatment. ADVERTISEMENT Johnson's blue urine isn't the only cutting-edge experiment he's trying. Just days before announcing his methylene blue regimen, he started a new therapy called IHHT—Intermittent Hypoxia-Hyperoxia Training—a technique that mimics altitude shifts by alternating oxygen levels through a mask. The science behind IHHT, according to Vitology, suggests it may enhance energy production, cognitive performance, heart health, and even slow the aging process. It's non-invasive and gaining traction in longevity clinics worldwide. But like most things in Johnson's protocol, it's still experimental. As promising as some of these interventions seem, they lack long-term data and broad clinical endorsement. Whether it's by injecting youthful plasma or peeing blue, Bryan Johnson continues to push the boundaries of what's possible—or permissible—in the name of never growing old. While his methods may seem eccentric or extreme, they force a larger conversation: how far are we willing to go to outsmart time?
Hindustan Times
12 hours ago
- Hindustan Times
The Political Race for Fewer Cures
America is leading the world into a new era of medical cures and biologic treatments, and the benefits to human health promise to be staggering. Yet why is America's political class—first Democrats and now Republicans—working hard to delay and maybe forestall this progress? Democrats have done much harm already with their Inflation Reduction Act price controls, as research and venture funding have declined. Now comes President Trump, who last week threatened drug companies with price controls or worse if they don't cut prices as he wants. Mr. Trump's excuse is that other countries are 'free riding' on American innovation. His solution: Demand manufacturers give Americans their 'most-favored nation' (MFN) price—i.e., the lowest in other developed countries like Canada and the U.K. If drug makers refuse, he may yank their drug approvals, harass them with lawsuits and more. 'If you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,' Mr. Trump wrote to 17 large drug makers on Thursday. *** It's true that countries with government-run health systems like Canada, the U.K. and France pay less for drugs than Medicare and U.S. private insurers do. But the price disparities Mr. Trump cites don't include all the discounts that U.S. manufacturers provide insurers, hospitals, pharmacies and the feds. A Berkeley Research Group study last year found that drug makers received about 50% on a dollar of revenue for every drug they sold in the U.S. The rest was paid out in fees and discounts to intermediaries and the government. Some discounts are passed onto Americans through lower insurance premiums, though some boost hospital and insurer profits. Medicare and Medicaid spent $181 billion on prescription drugs in 2023 versus $662 billion for hospitals. Patient out-of-pocket spending on prescription drugs accounts for about 1% of U.S. healthcare spending. Drugs aren't the main driver of healthcare premiums, patient costs or government spending. Manufacturers benefit for a few years from patent protection after medicines launch, but then they face stiff competition from follow-on medicines and generics. Prices typically fall by more than half after patent protection ends. Sales of AbbVie's auto-immune blockbuster Humira have shrunk by more than half since its patent monopoly ended in 2023. Unbranded generics in the U.S. make up 90% of all prescriptions and cost one-third less than in other economically developed countries, according to RAND. Generics also make up a much larger share of prescriptions in the U.S. than in other countries. That's because higher manufacturer list prices provide an incentive to develop biosimilars and generics. This market competition can reduce prices more than government price controls while providing an incentive for drug makers to continue to innovate. Mr. Trump's order would do the opposite by discouraging development of generics and new breakthrough treatments. Mr. Trump claimed last week that drug manufacturers receive 'generous research subsidies.' Not true. Universities do, and some of their research can lead to future drugs. But the pharmaceutical industry spent $141 billion on research and development in 2022, nearly 40 times as much as the National Institutes of Health did on research directly related to drug development. Browbeating companies, as Mr. Trump is doing, could spur them to move more intellectual property to China, where Xi Jinping is rolling out the red carpet. And it will likely result in fewer new drugs developed and sold in the U.S., especially in riskier research fields like neurologic and rare genetic diseases. If drug makers refuse Mr. Trump's MFN price, he has directed his Attorney General and Federal Trade Commission to take antitrust 'enforcement action.' Mr. Trump also ordered his Food and Drug Administration Commissioner Marty Makary to modify or revoke approvals 'for those drugs that maybe be unsafe, ineffective, or improperly marketed.' Translation: Nice medicine you have there. Terrible if something happened to it. *** It's not clear what legal authority Mr. Trump plans to invoke to do any of this, and it would presumably need a rule-making that could be challenged in court. His plan appears to usurp Congress's power over commerce and violate the Supreme Court's major questions doctrine. It may also violate due process and property and contractual rights. Mr. Trump had a chance to include drug prices in his trade negotiations with other countries. But he failed to do so with Europe and Japan. Instead he is now going to import foreign price controls to punish U.S. companies—and the Americans who will get fewer cures as a result.
